¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"adrenergic neuronal blocking agent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • anorectic agent
    ½Ä¿å¾ïÁ¦Á¦
  • antiallergic agent
    ¾Ë·¹¸£±â¾à
  • antiarrhythmic agent
    Ç׺ÎÁ¤¸ÆÁ¦
  • antiasthmatic agent
    Ç×õ½ÄÁ¦
  • antifoaming agent
    Ç×±âÆ÷Á¦, ±âÆ÷Á¦°ÅÁ¦
  • antifungal agent
    Ç×Áø±ÕÁ¦
  • antiinflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
  • antiviral agent
    Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×¹ÙÀÌ·¯½º¹°Áú
  • agent
    1. ¹°Áú 2. ÀÎÀÚ 3. -¾à, -Á¦
  • alkylating agent
    ¾Ëųȭ¾à¹°, ¾ËųȭÁ¦
  • anesthetic agent
    ¸¶ÃëÁ¦
  • biologic agent
    »ý¹°ÇÐÀûÁ¦Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pressor agent
    ½Â¾ÐÁ¦, Ç÷¾Ð»ó½ÂÁ¦
  • sclerosing agent
    °æÈ­Á¦
  • tocolytic agent
    ÀڱüöÃà¾ïÁ¦Á¦
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • blocking test
    Â÷´Ü½ÃÇè
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø½Å°æ±ÙÂ÷´ÜÁ¦
  • ganglionic blocking drug
    ½Å°æÀýÂ÷´Ü¾àÁ¦
  • agent
    ¾à¹°, ¾àÁ¦, ¹°Áú, ÀÎÀÚ, ¹ß»ý¿ø
  • alkylating agent
    ¾Ëųȭ¾à¹°, ¾ËųȭÁ¦
  • anesthetic agent
    ¸¶ÃëÁ¦
  • anorectic agent
    ½Ä¿å°¨ÅðÁ¦
  • anti-inflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • antiallergic agent
    ¾Ë·¹¸£±â¾à
  • antiarrhythmic agent
    Ç׺ÎÁ¤¸ÆÁ¦
  • antiasthmatic agent
    (¢¡antasthmatic) Ç×õ½ÄÁ¦
  • antifoaming agent
    Ç×±âÆ÷Á¦, ±âÆ÷Á¦°ÅÁ¦
  • antifungal agent
    Ç×Áø±ÕÁ¦
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
  • genetic blocking
    À¯ÀüÀû Â÷´Ü(ë¶îîîÜó´Ó¨).
  • genetic blocking
    À¯ÀüÀû Â÷´Ü.
  • Eaton agent
    ÀÌÆ°º´¿øÃ¼.
  • Eatons agent
    ÀÌÆ°º´¿øÃ¼.
  • Eatons agent
    ÀÌÆ°º´¿øÃ¼.
  • Eatons agent
    ÀÌÆ° º´¿øÃ¼
  • Eatons agent pneumonia
    ÀÌÆ°º´¿øÃ¼Æó·Å.
  • Norwalk agent
    ³ë¿öÅ© º´¿øÃ¼
  • Norwalk-like agent
    ³ë¸£¿ÍÅ©¾ç ü
  • Parvovirus-like agent
    ÆÄº¸¹ÙÀÌ·¯½º¾ç º´¿øÃ¼
  • Pittsburgh pneumonia [agent]
    ÇÇÃ÷¹ö±×Æó·Å(¿øÀÎü), ·¹Áö¿À³Ú¶óÁõ(¿øÀÎü)
  • addition agent
    ÷°¡Á¦(ôÕÊ¥ð¥).
  • alpha-sympathomimetic agent
    ¾ËÆÄ±³°¨½Å°æÀ¯»çÀÛ¿ëÁ¦
  • anesthetic agent
    ¸¶Ãë¾à, ¸¶ÃëÁ¦.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦.
  • neuromuscular blocking agent
    ½Å°æ±ÙÂ÷´Ü<ºÀ¼â>Á¦(¾à).
  • neuromuscular blocking agent
    ½Å°æ±ÙÂ÷´ÜÁ¦, ½Å°æ±ÙÂ÷´Ü¾à(~ó´Ó¨å·).
  • receptor blocking agent
    ¼ö¿ëüÂ÷´Ü<ºÀ¼â>Á¦.
  • sympathetic blocking agent
    ±³°¨½Å°æÂ÷´Ü<ºÀ¼â>Á¦.
  • adrenergic
    ¾Æµå·¹³¯¸°¼º, ¾Æµå·¹³¯¸°ÀÛµ¿¼º, ¾Æµå·¹³¯¸°(¼º)¾à.
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼ºÃËÁøÁ¦
  • adrenergic antagonist
    ¾Æµå·¹³¯¸° ±æÇ×¹°Áú
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°¼º ±æÇ×Á¦
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼º ¼¶À¯
  • adrenergic neuron
    ¾Æµå·¹³¯¸°¼º ½Å°æ
  • adrenergic neurotransmitter
    ¾Æµå·¹³¯¸°¼º ½Å°æÀü´Þ¹°Áú
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â,°¨¼öü)
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°ÈïºÐ¾à, ¾Æµå·¹³¯¸°ÀÚ±ØÁ¦.
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°(¼º)ÈïºÐ¾à, ¾Æµå·¹³¯¸°(¼º)ÀÚ±ØÁ¦.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bactericidal agent
    »ì±ÕÁ¦(߯жð¥)
  • bacteriostatic agent
    Á¤±ÕÁ¦(ð¡Ð¶ð¤)
  • chaotropic agent
    ¹«Áú¼­À¯¹ßÁ¦(Ùíòñßíë¯Û¡ð¥)
  • chelating agent
    ų·¹ÀÌÆ®Á¦(ð¥)
  • chemotherapeutic agent
    È­Çпä¹ýÁ¦(ûùùÊÖûÛöð¥)
  • cytostatic agent
    ¼¼Æ÷Áõ½Ä¾ïÁ¦Á¦(á¬øàñòãÖåäð¤ð¥)
  • denaturing agent
    º¯¼ºÁ¦(ܨàõð¥)
  • eluting agent
    ¿ë¸®Á¦(éÁ×îð¥)
  • emulsifying agent
    ¿¡¸ÖÁ¯È­Á¦(ûùð¥)
  • F agent
    F Á¦(ð¥)
  • fusogenic agent
    À¶ÇÕ »ý¼ºÁ¦(ë×ùêßæà÷ð¥)
  • germicidal agent
    »ì±ÕÁ¦(߯жð¥)
  • immunosuppressive agent
    ¸é¿ª¾ï¾ÐÁ¦(Øóæ¹åääâð¥)
  • lipotropic agent
    ÁöÁúµ¿¿øÁ¦(ò·òõÔÑê¬ð¥)
  • lympholytic agent
    ¸²ÇÁ±¸¿ëÇØÁ¦(éÁú°ð­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radioopaque agent
    ¹æ»ç¼±ºñÅõ°ú¼ºÁ¦Àç
  • radioprotective agent
    ¹æ»ç¼±¹æÈ£Á¦
  • sclerosing agent
    °æÈ­¾à
  • therapeutic agent
    Ä¡·á¾à
  • thrombolytic agent
    Ç÷Àü¿ëÇØ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LNP large neuronal polypeptide
NCL neuronal ceroid-lipofuscinosis; nucleolin
SCN1A sodium channel, neuronal alpha-subunit type 1
BA Bachelor of Arts; backache; bacterial agglutination; basilar artery; basion; benzyladenine; best amp...
ADRA1C alpha-1C-adrenergic receptor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NMB neuromuscular blocking
a Agent
CAA Chicken anaemia agent
FWA fluorescent whitening agent
SMA Snow Mountain Agent
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adrenergic neurotransmitter
    ¾Æµå·¹³¯¸°¼º ½Å°æ Àü´Þ ¹°Áú
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adrenergic transmission
    ¾Æµå·¹³¯¸°¼º Àü´Þ
    ³ë¸£¾Æµå·¹³¯¸° ¶Ç´Â ¾Æµå·¹³¯¸°À» Àü´Þ ¹°Áú·Î ÇÏ´Â ÈïºÐ Àü´Þ. ±³°¨½Å°æÀÇ ¹ß´ÜÀ» °ÅÀÇ À̰ÍÀÌ´Ù. ±³°¨ ½Å°æ ¼¶À¯°¡ ÈïºÐÇÏ¸é ¸»´Ü¿¡¼­ ³ë¸£¾Æµå·¹³¯¸° µîÀÌ ¹æÃâµÇ°í À̰ÍÀÌ È¿°ú±âÀÇ ¼ö¿ë±â¿¡ µµ´ÞÇØ ÈïºÐµÈ´Ù. ÈïºÐ
  • adrenergic urticaria
    ¾Æµå·¹³¯¸°¼º µÎµå·¯±â
  • alpha 1-adrenergic blocker
    ¾ËÆÄ 1-¾Æµå·¹³¯¸°¼º Â÷´Ü
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • ¥â-adrenergic

    ¥â-adrenergic agent (

    ¥â-adrenergic receptor blocking agent (º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü Â÷´ÜÁ¦

  • blocking
    Â÷´Ü, ºÀ¼â, Â÷´Ü¾à, ºÀ¼â¾à, Á¡Âø
    1. ±¸½É¼º ½Å°æ·ÎÀÇ Â÷´Ü, ¿¹ÄÁµ¥ ÄÚÄÉÀÎ ÁÖ»ç·Î ÀÎÇÑ Â÷´Ü. ¼¼Æ÷³» »ýÇÕ¼º °úÁ¤ÀÇ ÀúÁö. 2. ¾î¶² ÄÞÇ÷º½º¿¡ ºÎµúÃÆÀ» ¶§ °©ÀÛ½º·± ¿¬»óÀÇ Á¤Áö¿¡ ´ëÇÑ ÇÁ·ÎÀ̵åÇÐÆÄÀÇ ¿ë¾î. 3. ¼¿·ÎÀ̵òÀ¸·Î ħÅõ½ÃŲ Á¶Á÷ Ç¥º»À» ¸ñÆíÀ̳ª ±âŸ ´Ù¸¥ Àû´çÇÑ ¹°Áú·Î °íÁ¤½ÃÄÑ ¸¶ÀÌÅ©·ÎÅè¿¡ ºÎÂø½Ãų ¼ö ÀÖ°Ô ÇÏ´Â °Í.
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
  • blocking effect
    Â÷´Ü È¿°ú
  • blocking of thought
    »ç°íÀúÇØ
    Á¤½ÅºÐ¿­Áõ¿¡¼­ º¼ ¼ö ÀÖ´Â °ÍÀ¸·Î¼­ ȯÀÚÀÇ È£¼Ò´ë·Î »ç°íÀÇ ±æÀÌ ¸·Çô¼­ ÀÚ½ÅÀ» Ç¥ÇöÇÏ´Â °ÍÀÌ ¾î·Á¿î Á¤½Å »óÅÂ.
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±Ù ºÀ¼â ¾à¹°
  • nerve blocking
    ½Å°æ Â÷´Ü, ½Å°æ Â÷´Ü¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
neuronal hyperplasia Increased numbers of ganglion cells with myenteric plexus hyperplasia and increased acetylcholinesterase activity in nerves of the mucosa and submucosa. Clinically, neuronal hyperplasia mimics Hirschprung's disease. Similar findings are seen in patients with multiple endocrine neoplasia syndrome, type IIB, and in neurofibromatosis.
Synonym: hyperganglionosis, neuronal intestinal dysplasia.
(05 Mar 2000)
neuronal intestinal dysplasia Increased numbers of ganglion cells with myenteric plexus hyperplasia and increased acetylcholinesterase activity in nerves of the mucosa and submucosa. Clinically, neuronal hyperplasia mimics Hirschprung's disease. Similar findings are seen in patients with multiple endocrine neoplasia syndrome, type IIB, and in neurofibromatosis.
Synonym: hyperganglionosis, neuronal intestinal dysplasia.
(05 Mar 2000)
neuronal plasticity Ability of nerve cells to change their properties for example by sprouting new processes, making new synapses or altering the strength of existing synapses.
See: long-term potentiation.
(18 Nov 1997)
neuronal polarity Distribution of specific functions to discrete cellular domains: for example axons and dendrites that have different molecular composition, morphology and ultrastructure and perform different functions.
(18 Nov 1997)
infantile neuronal degeneration <neurology, paediatrics> Degenerative disorder of infants with widespread neuronal loss in thalamus, cerebellum, pons, and spinal cord, resembling infantile muscular atrophy.
(05 Mar 2000)
alpha blocking The attenuation of the occipital alpha rhythm (8-14 Hz brain waves as seen on an electroencephalogram), produced by opening the eyes or by intense mental concentration.
(05 Mar 2000)
antibodies, blocking Antibodies that inhibit the reaction between antigen and other antibodies or sensitised T-lymphocytes (e.g., antibodies of the IgG class that compete with IgE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumours and prevent destruction of tumour cells by cytotoxic T-lymphocytes have also been called enhancing antibodies.
(12 Dec 1998)
blocking 1. Obstructing; arresting of passage, conduction, or transmission.
2. In psychoanalysis, a sudden break in free association occurring when a painful subject or repressed complex is touched.
3. Sudden cessation of thoughts and speech, which may indicate the presence of a severe thought disorder or a psychosis.
(05 Mar 2000)
blocking activity The repression or elimination of electrical activity in the brain by the arrival of a sensory stimulus.
(05 Mar 2000)
blocking antibody An antibody used in a reaction to prevent some other reaction taking place, for example one antibody competing with another for a cell surface receptor.
See: desensitisation.
(18 Nov 1997)
Rh blocking test A test for nonagglutinating Rh antibodies: an Rh agglutination test is first carried out; if the test for Rh agglutinins is negative, then 1 drop of anti-Rho agglutinating serum of moderate titre is mixed with the patient's serum containing Rh-positive test cells; if after incubating for from 1 to 2 hr at 37°C no agglutination occurs, Rho-blocking antibodies are assumed to be present in the patient's serum.
(05 Mar 2000)
spermatogenesis-blocking agents Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa.
(12 Dec 1998)
neuromuscular blocking agents Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarising agents) or noncompetitive, depolarising agents (neuromuscular depolarising agents). Both prevent acetylcholine from triggering the muscle contraction and they are used as anaesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.
(12 Dec 1998)
adrenergic <neurology, physiology> Refers to neurons that use catecholamines as neurotransmitters at a synapse when a nerve impulse passes i.e. The sympathetic fibres.
Also refers to neurones that are activated by, characteristic of or secreting adrenaline (adrenaline) or substances with similar activity.
(15 Jan 1998)
adrenergic agents Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fiscal agent
    À繫 ´ë¸® ±â°ü;À繫 ´ë¸®ÀÎ
  • forwarding agent
    ¿î¼Û¾÷ÀÚ
  • free agent
    ÀÚÁÖÀûÀÎ ÇàÀ§ÀÚ;ÀÚÀ¯°è¾à ¼±¼ö )
  • general agent
    ÃѴ븮ÀÎ
  • house agent
    º¹´ö¹æ;°¡¿Á ¸Å¸Å ¼Ò°³¾÷ÀÚ
  • inquiry agent
    (¿µ)»ç½Ç ŽÁ¤
  • insurance agent
    º¸Çè´ë¸®Á¡
  • land agent
    ÅäÁö ¸Å¸Å Áß°³¾÷ÀÚ;ÅäÁö °ü¸®ÀÎ
  • nerve agent
    (±º¿ëÀÇ)½Å°æ°è¿¡ ÀÛ¿ëÇÏ´Â ¹°Áú;½Å°æ°¡½º(µî)
  • parliamentary agent
    Á¤´çÀÇ ÀÇȸ ´ëº¯ÀÎ
  • press agent
    º¸µµ¿ø;¼±Àü¿ø
  • publicity agent
    ±¤°í ´ë¸®¾÷ÀÚ
  • purchasing agent
    ±¸¸Å ´ã´ç
  • reducing agent
    ȯ¿øÁ¦
  • road agent
    ³ë»ó°­µµ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á